Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation

Figures

• 

  Figure 1. Efficacy and safety outcomes with NOAC compared with warfarin in 18638 NOAC patients with 14 457 years of risk and 49 418 warfarin patients with 75 747 person-years at risk. Multivariable Fine-Gray competing risks models were used to evaluate the association between outcomes and treatment regime, accounting for the competing risk of death for all outcomes except all-cause mortality. Multivariable Cox regression was used to evaluate the association between mortality and treatment regime. Multivariable adjustments for age (continuous), gender, marital status, immigrant status, higher education (>12 years), income in the top quartile, first atrial fibrillation diagnosis within 3 months before index, intracranial bleed, gastrointestinal bleed, urogenital bleed, other bleed, anaemia, coagulation or platelet defect, renal failure, liver disease, ischaemic stroke, heart failure, hypertension, diabetes, myocardial infarction, valvular disease (other than exclusion criteria), pacemaker/implantable cardioverter defibrillator, thyrotoxicosis with preceding years, hypothyroidism, chronic obstructive pulmonary disease, asthma, pulmonary embolism, cancer within 3 years, alcohol index,…

• 

  Figure 2. Patient flow chart. NOAC, non-vitamin K antagonist oral anticoagulant.

• 

  Figure 3. Subgroup analyses of all-cause stroke or systemic embolism, NOAC compared with warfarin. NOAC, non-vitamin K antagonist oral anticoagulant; TIA, transient ischaemic attack.

• 

  Figure 4. Subgroup analyses of major bleeding events, NOAC compared with warfarin. NOAC, non-vitamin K antagonist oral anticoagulant; TIA, transient ischaemic attack.

• 

  Figure 5. Subgroup analyses of all-cause mortality, NOAC compared with warfarin. NOAC, non-vitamin K antagonist oral anticoagulant; TIA, transient ischaemic attack.